EPISTEME
PROGNOSTICS

Personalized Epigenetics™

Founded in February 2019, raising the seed / series A round

EPISTEME OFFERS A SOPHISTICATED PERSONALIZED THERAGNOSTIC TEST FOR ALL CANCER PATIENTS

- Cancer patients, after the first diagnosis often ask, "how *bad* is my tumor and what should I do if it is *bad*?"
- In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die
- Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy
- Episteme invented a novel microarray-based platform technology called **"ATAC-Array"**. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – ***the only microarray that reads chromatin accessibility***
- ***No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary***
- Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy *for better outcome and better quality of life*
- It can be easily performed on tumor biopsy/surgically resected tumor specimens with results provided in 3 days

VALUE PROPOSITION

- Increase the probability of success of clinical trials with epigenetic drugs and can develop companion diagnostics
- Enable clinicians to begin this advantageous therapeutic stratification for patients ***at the time of diagnosis***
- Long-term goal is to implement this into a clinical setting as a routine theragnostic test for ***all*** cancer patients, stratifying them for the best personalized outcomes

MILESTONES AND STATUS

- Assay is fully developed and ready to launch in the clinical trial market
- Proof of concept completed on 38 human pancreatic ductal adenocarcinoma (PDAC) patients with successful prediction of patients who would recur early and those who would not (Gehan-Breslow-Wilcoxon test p=0.0076)
- Our potential customer engaging is actively in process

EPISTEME STRATIFICATION PROCESS FLOW

- Collect biopsy/surgically resected tumor specimens -> ATAC-libraries from tumor cells -> perform ATAC-array
- Collect the paraffin blocks/slides and perform immunohistochemistry analysis of transcription factors
- Call for the– "high-risk" or "low-risk" groups -> the high-risk patient will be suggested to combine with an epigenetic (reprograming) therapy and the "low-risk" patients may continue with the standard chemotherapy.

THE TEAM

- Co-founder, President & CSO, **Surajit Dhara**, Senior Research Scientist at the Dartmouth-Hitchcock Norris Cotton Cancer Center (DHNCCC)
- Co-founder & Chair of the Scientific Advisory Board, **Steven D. Leach**, the Director of the DHNCCC
- Advisor, **Jason Rifkin**, President & CEO of PhageNova Bio, Inc.
- Advisor, **Juan-Carlos Serna** Co-founder, President & CEO of Right Submission, LLC
- Advisor, **Pradip K Majumder**, Co-founder & former CSO of Mitra Biotech, Inc.
- Advisor, **Jake M. Reder**, Co-founder, President & CEO of Celdara Medical, LLC
- Advisor, **Caroline Cannon**, Associate Director, Career Development, Tuck School of Business, Dartmouth College
- Clinical Collaborator, **Kerrington Smith,** is the Division Chief, Surgical Oncology, DHNCCC
- Clinical Collaborator, **Jason E. Faris,** is the Director of the Early Phase Trial Program at the DHNCCC
- Clinical Collaborator, **Arindam Dhar,** Executive Director, Early Development Lead, Cancer Epigenetics, GlaxoSmithkilne

MARKET SIZE

- Total available market (TAM) is 18.1 million new cancer cases worldwide and 1.76 million in the USA every year. Currently, 138 clinical trials on epigenetic drugs are registered by 31 pharmaceutical companies.
- Our pilot market is pancreatic cancer cases (total 56K new cases per year in the USA and 458,918 world-wide) in New England and New York area, after which we will expand geographically as well as into new indications.
- Personalized therapy is the future of cancer care. Our technology and business model are low risk with high potential to change lives. Funding translates directly to the speed with which we can scale the business.
- We are raising **$5M** to aggressively enter into the market.

16 Cavendish Court, DRTC, Suite 423 Lebanon, 03766, USA E-mail: dharasur70@gmail.com